A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

Also called NCT04309474

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
  • AbbVie Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04309474
  • EudraCT 2019-003753-29
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Japan, South Korea, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04309474. Randomized; triple masking; primary purpose treatment. Start 2020-11-09 (actual); primary completion 2024-04-18 (actual). Results posted on 2025-12-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
Acronym
EAISE
Condition
Acute Ischemic Stroke
Intervention (Drug)
Elezanumab
Intervention (Drug)
Placebo
Lead sponsor
AbbVie (class: industry)

Record details

Record id
cardio:ct-nct04309474
Content hash
c9f50fff304c93e0021aba046d4dcf269d758825f2efdec21b313f1ebeed9795